 Voyager Therapeutics Inc NASDAQ: VYGR announced preclinical data from a new vectorized anti-HER2 antibody program. Data showed that IV dosing of a proprietary AAV vector identified by the TRACER screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in animal models of brain metastases. 